Browse EX-10 agreements

RECIPROCAL LOAN AGREEMENT

This RECIPROCAL LOAN AGREEMENT (this “Agreement”), dated as of April 1, 2026, between Voya Retirement Insurance and Annuity Company, a Connecticut life insurance company (“VRIAC” or “Company”), located at One Orange Way, Windsor, Connecticut 06095 and Voya Financial, Inc., a Delaware corporation (“Voya Financial” or “Company”), located at 200 Park Avenue, New York, New York 10166 (collectively referred to as the "Companies").

WITNESSETH:

WHEREAS, each of the Companies may have, from time to time, a need to borrow funds on a revolving basis; and

WHEREAS, each of the Companies may have, from time to time, excess cash available to lend to the other on a revolving basis; and

WHEREAS, the Companies are affiliated entities and as such are willing to extend financing to, and borrow from each other as provided herein; and

WHEREAS, each of the Companies desires to enter into this Agreement providing for, among other things, the making of such Loans by and among each other;

…

SOLID BIOSCIENCES INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The non-employee directors of Solid Biosciences Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors of the Company (the “Board”).

Director Compensation

Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company’s affairs. We also seek to align the interests of our directors and our stockholders, and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.

Cash Compensation

The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of each committee of the Board will be as follows:

…

HSBC INSTITUTIONAL TRUST SERVICES (SINGAPORE) LIMITED AS TRUSTEE OF CAPITALAND ASCENDAS REIT

and

AMBIQ MICRO SINGAPORE PRIVATE LTD.

Lease for

10 KALLANG AVENUE

#14-10 TO #14-13 APERIA

SINGAPORE 339510

---

SCHEDULE 1 DETAILS OF LEASE

Item 1:	Landlord (we, us, our)	:	HSBC INSTITUTIONAL TRUST SERVICES (SINGAPORE) LIMITED AS TRUSTEE OF CAPITALAND ASCENDAS REIT
Item 2:	Tenant (you, your)	:	AMBIQ MICRO SINGAPORE PRIVATE LTD.
Item 3:	Premises
	(a) Unit numbers	:	#14-10 to #14-13 Aperia
	(b) Building	:	10 Kallang Avenue Aperia Singapore 339510
	(c) Boundary	:	(for identification only) edged in red in the attached plan (or plans), marked as schedule 5
Item 4:	Floor Area	:
	Unit numbers #14-10 to #14-13 Aperia Total Floor Area		Floor Area (square metre) 875.45 875.45
Item 5:	Possession Date	:	15 January 2026
Item 6:	Start Date	:	15 March 2026

…

EXCLUSIVE LICENSE AGREEMENT

This  Exclusive License Agreement (this “Agreement”) is effective as of March 15, 2026 (the “Effective Date”) and made and entered into on May 8, 2026 (the “Execution Date”), by and between Impetis Biosciences Limited, a company incorporated in India, having a place of business at address of 6th Floor, Wing E, Times Square, Marol, Andheri-Kurla Road, Gamdevi, Andheri-East, Mumbai, 400059, Maharashtra, India (“Licensor”), and Vyome Holdings, Inc., a Delaware corporation having its principal office at Harvard Square One Mifflin Place, Suite 400, Cambridge, MA 02138 (the “Licensee” and together, with the Licensor, the “Parties” and each a “Party”).

Recitals

WHEREAS, Licensor is in the business of progressing its high-value assets through collaborations and partnerships in order to transform the lives of patients suffering from diseases that have no or limited therapeutic choices;

…

Exhibit 10.6

AMENDMENT NO. 2 TO CONSULTING AGREEMENT

This AMENDMENT NO.2 (“Amendment No. 2”) to the CONSULTING AGREEMENT dated April 11, 2024 and amended November 21, 2024 (the “Agreement”) between OPUS GENETICS INC., a Delaware corporation having its principal place of business at 8 Davis Drive, Durham, NC, 27713 (the “Company”), and JAY S. PEPOSE MD, whose address is 1125 Templeton Place, Chesterfield, MO 63017 (“Consultant”) is made as of April 10, 2026 (the “Effective Date”).

I.The term of the Agreement shall be extended to May 11, 2026.

II.All other terms of the Agreement remain in effect without change.

Having understood and agreed to the foregoing, the Company and Consultant have signed this Amendment No.2 and the same shall be effective as of the Effective Date.

IN WITNESS WHEREOF, the parties have, by duly authorized persons, executed this Agreement as of the Effective Date.

…

Exhibit 10.5

Executed Version

WAIVER AND OMNIBUS AMENDMENT OF

NOTE PURCHASE AGREEMENT

AND

STOCK PURCHASE AND CONVERSION AGREEMENT

April 13, 2026

This Waiver and Omnibus Amendment (this “Amendment”), dated as of the date first set forth above, is entered into by and among Opus Genetics, Inc., a Delaware corporation (the “Company”), OpusTX, LLC, a Delaware limited liability company (the “Guarantor” and, together with the Company, the “Obligors” and each, an “Obligor”), the Persons listed on the signature pages hereof under the heading “PURCHASERS” (each a “Purchaser” and, collectively, the “Purchasers”), and OPCM SA LLC, a Delaware limited liability company (“Purchaser Agent”).

…

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

PALISADE BIO, INC.

Equity Award Policy

Introduction.

This Equity Award Policy (the “Policy”) specifies the treatment of each Equity Award granted by Palisade Bio, Inc. (including any successor thereto, the “Company”) or an Affiliate of the Company to the Company’s officers, employees and non-employee directors (a “Grantee”) in the event of the death of such a Grantee. This policy does not apply to (a) advisors or consultants of the Company who hold Equity Awards, (b) an Equity Award held by an individual or entity other than the Grantee, or (c) shares purchased or awards granted pursuant to the Company’s Employee Stock Purchase Plan, as may be amended or replaced. Capitalized terms used in the Policy are defined in Section 3, except as otherwise specified.

Effectiveness; Amendment; Termination.

…

RALLIANT CORPORATION

2025 STOCK INCENTIVE PLAN

PERFORMANCE STOCK UNIT AGREEMENT

Unless otherwise defined herein, the terms defined in the Ralliant Corporation 2025 Stock Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Stock Unit Agreement, including the Restrictive Covenant Addendum attached hereto as Addendum B and any additional terms and conditions for the Participant’s country set forth in the addendum attached hereto as Addendum C (the “Addendum C”) (collectively, the “Agreement”).

I.NOTICE OF GRANT

Name:

The undersigned Participant has been granted an Award of Performance Stock Units, subject to the terms and conditions of the Plan and this Agreement, as follows (each of the following capitalized terms are defined terms having the meaning indicated below):

Date of Grant:

Target PSUs:

Performance Period:    January 1, [____] through December 31, [____]

Vesting Conditions:     Per this Agreement (including Addendum A)

II.AGREEMENT

…

RALLIANT CORPORATION

2025 STOCK INCENTIVE PLAN

RESTRICTED STOCK UNIT AGREEMENT

Unless otherwise defined herein, the terms defined in the Ralliant Corporation 2025 Stock Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement, including the Restrictive Covenant Addendum attached hereto as Addendum B and any additional terms and conditions for the Participant's country set forth in the addendum attached hereto as Addendum C (the “Addendum C”) (collectively, the “Agreement”).

I.NOTICE OF GRANT

Name:

The undersigned Participant has been granted an Award of Restricted Stock Units, subject to the terms and conditions of the Plan and the Agreement, as follows (each of the following capitalized terms are defined terms having the meaning indicated below):

Date of Grant

Number of Restricted Stock Units

Vesting Schedule

Time-Based Vesting Criteria    The RSUs will vest pursuant to the Vesting Schedule noted above.

Performance Objective    Set forth on Addendum A (if applicable)

II.AGREEMENT

…

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Omitted Information is indicated by [***]

EXECUTIVE RELEASE OF CLAIMS

This Executive Release of Claims (this “Release”) is entered into this 7th day of May 2026, (the “Agreement Date”) by and between GBT US LLC, a Delaware limited liability company (the “Company”), and John David Thompson (the “Executive,” together with the Company, the “Parties”).

WHEREAS, the Executive is employed by the Company as its EVP, Chief Technology Officer;

WHEREAS, the Executive’s employment relationship with the Company as well as all other positions that the Executive holds with Global Business Travel Group, Inc., a Delaware corporation (“GBTGI”), will terminate on May 31, 2026 (the “Termination Date”), upon the terms set forth herein.

…

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Omitted Information is indicated by [***]

SEVERANCE PROTECTION AGREEMENT

This Severance Protection Agreement (this “Agreement”) is entered into as of November 29, 2021 by and between GBT US LLC, a Delaware limited liability company (the “Company”), and John David Thompson (the “Executive”). This Agreement shall become effective upon the Company or its ultimate parent entity (currently GBT JerseyCo Limited) having a class of common stock publicly traded on a national securities exchange, such as the New York Stock Exchange, or quoted on NASDAQ (the date on which this Agreement becomes effective is referred to herein as the "Effective Date"); provided, however, that if the Effective Date does not occur on or before July 31, 2022, then this Agreement shall be null and void ab initio and neither party hereto shall have any liabilities or obligations hereunder.

Recitals

…